Candel Therapeutics Inc (CADL) — Cash Flow-to-Debt Ratio
Candel Therapeutics Inc (CADL) has a Cash Flow-to-Debt Ratio of -0.14x as of December 2025, meaning its operating cash flow of $-10.57 Million could theoretically repay 0% of its total liabilities ($73.27 Million) in one year. See CADL working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Candel Therapeutics Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Candel Therapeutics Inc across 7 annual periods. Also explore Candel Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Candel Therapeutics Inc (2019–2025)
Year-by-year debt coverage analysis for Candel Therapeutics Inc. For market capitalisation and broader financial context, see Candel Therapeutics Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.52x | $-38.31 Million | $73.27 Million | ▲ +21.6% |
| 2024 | -0.67x | $-27.02 Million | $40.54 Million | ▲ +44.6% |
| 2023 | -1.20x | $-34.24 Million | $28.46 Million | ▼ -18.0% |
| 2022 | -1.02x | $-31.42 Million | $30.80 Million | ▼ -15.1% |
| 2021 | -0.89x | $-22.22 Million | $25.07 Million | ▼ -504.3% |
| 2020 | -0.15x | $-9.07 Million | $61.84 Million | ▼ -52.8% |
| 2019 | -0.10x | $-5.18 Million | $53.94 Million | — |